Targeted cancer prevention programs are available for confirmed carriers of pathogenic gene variants associated with hereditary breast and ovarian cancer (BRCA1, BRCA2, PALB2) or Lynch syndrome (MLH1, MSH2, MSH6, PMS2). Here, MSH6 is linked to Hereditary breast and ovarian cancer syndrome.